Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | FPR3 | P25089 | 2/20 | 0.33 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7370346 | 0.76 | MME (0.39) | ALDH1A1CYP2C9CYP2C19MMEL3MBTL1 | |
| SCHEMBL3583292 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2RAB9AGAAMMP2MMP8 | |
| SCHEMBL988593 | 0.74 | CYP1A2 (0.38) | SMN1; SMN2RAB9AALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL15592337 | 0.72 | SMN1; SMN2 (0.40) | SMN1; SMN2RAB9AGAAMMP2MMP8 | |
| SCHEMBL1063404 | 0.69 | CYP2C19 (0.40) | SMN1; SMN2RAB9ACYP1A2CYP2C19MME | |
| SCHEMBL29184375 | 0.68 | NPSR1 (0.40) | ALDH1A1CYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL19199227 | 0.68 | SMN1; SMN2 (0.42) | SMN1; SMN2RAB9AGAAMMP2MMP8 | |
| SCHEMBL9034015 | 0.68 | CYP1A2 (0.34) | CYP1A2CYP2C19 | |
| SCHEMBL20806732 | 0.67 | SMN1; SMN2 (0.42) | SMN1; SMN2RAB9AGAAMMP2MMP8 | |
| SCHEMBL3587681 | 0.67 | SMN1; SMN2 (0.40) | SMN1; SMN2RAB9AGAAMMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390896-B2 | Cyclic malonamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-06-24 | — | — | US | claimed |
| US-20080021014-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-24 | — | — | US | claimed |
| US-20100041639-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMAPNY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100009965-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-10-22 | — | — | US | disclosed |
| US-7528249-B2 | Cyclic malonamides as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080275024-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-06 | — | — | US | disclosed |
| US-7390896-B2 | Cyclic malonamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080021014-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-24 | — | — | US | disclosed |
| US-7276496-B2 | Cyclic malonamides as inhibitors of Aβ protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20060135762-A1 | Cyclic malonamides as inhibitors of Abeta protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-06-22 | — | — | US | disclosed |
| US-7053081-B2 | Cyclic malonamides as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050009807-A1 | Cyclic malonamides as inhibitors of A-Beta protein production | OLSON RICHARD E (US) | 2005-01-13 | — | — | US | disclosed |
| US-6759404-B2 | INHIBITING GAMMA-SECRETASE ACTIVITY; TREATING DISEASES ASSOCIATED WITH BETA-AMYLOID PRODUCTION, SUCH AS ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-07-06 | — | — | US | disclosed |
| EP-1268433-A1 | CYCLIC LACTAMS AS INHIBITORS OF A-BETA-PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020103184-A1 | Cyclic malonamides as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | disclosed |
| WO-2001074783-A1 | CYCLIC LACTAMS AS INHIBITORS OF A ΒΕΤΑ PROTEIN PRODUCTION | DUPONT PHARMACEUTICALS COMPANY (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135762-A1 | Cyclic malonamides as inhibitors of Abeta protein protection | APP, BACE1, APBA1 | SMN1; SMN2 636/4885RAB9A 1166/4885GAA 337/4885 |
| US-20020103184-A1 | Cyclic malonamides as inhibitors of a beta protein production | APP, BACE1, APH1A | SMN1; SMN2 795/4885RAB9A 870/4885GAA 118/4885 |
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | APP, BACE1, APBA1 | SMN1; SMN2 1078/4885RAB9A 1110/4885GAA 277/4885 |
| US-20100009965-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | APP, BACE1, APBA1 | SMN1; SMN2 1078/4885RAB9A 1110/4885GAA 277/4885 |
| US-20100041639-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | SMN1; SMN2 973/4885RAB9A 899/4885GAA 135/4885 |
| US-20080275024-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION | APP, BACE1, APH1A | SMN1; SMN2 944/4885RAB9A 351/4885GAA 63/4885 |
| US-20080021014-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | APP, BACE1, APBA1 | SMN1; SMN2 1078/4885RAB9A 1110/4885GAA 277/4885 |
| US-20050009807-A1 | Cyclic malonamides as inhibitors of A-Beta protein production | APP, APBA1, APH1A | SMN1; SMN2 1186/4885RAB9A 929/4885GAA 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.